Sickle Cell Disease Newborn Screening Follow-Up Program
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
HRSA will provide $65,500 in supplemental award funds to each of the 25 Sickle Cell Disease (SCD) Newborn Screening Follow-Up Program (NBS FP) grantees under HRSA-21-036 in fiscal year (FY) 2025, totaling $1,637,500. The FY 2025 supplemental funds will support grant activities that are in scope of program goals and objectives. The supplemental funding can support activities related to: increasing access to medical and support services, particularly during the pediatric to adult transition period; improving data systems; increasing workforce training and knowledge; expanding quality improvement projects; or conducting outreach to help identify individuals living with SCD who have been lost to follow-up. These activities will strengthen the linkage of individuals with SCD to appropriate and ongoing care to improve health outcomes.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.